Brief: Spero Therapeutics - On June 7, Co Entered Revenue Interest Termination Agreement With Healthcare Royalty Management
07/06/2022 21:55
June 7 (Reuters) - Spero Therapeutics Inc SPRO.O :
* SPERO THERAPEUTICS - ON JUNE 7, CO ENTERED REVENUE
INTEREST
TERMINATION AGREEMENT WITH HEALTHCARE ROYALTY MANAGEMENT
* SPERO THERAPEUTICS - PURSUANT TO TERMINATION AGREEMENT,
THE
COMPANY WILL MAKE A ONE-TIME CASH PAYMENT OF $54 MILLION - SEC
FILING
Further company coverage: SPRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)